Abstracts tagged "Infection"

Abstract Number: 1276 • 2013 ACR/ARHP Annual Meeting
Immunologic Monitoring and Infectious Complications In Pediatric Rheumatology Patients Treated With Rituximab
Alysha Taxter¹, Kathleen E. Sullivan² and Jon Burnham³, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rituximab is an anti-CD20 monoclonal antibody increasingly used in immunologic and malignant conditions to deplete B cells. Suppression of humoral immunity after rituximab exposure may…
Abstract Number: 1046 • 2013 ACR/ARHP Annual Meeting
Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination
Yunjun Luo¹, Diana L. Johnson², Ronghui Xu³ and Christina D. Chambers¹, ¹Pediatrics, University of California, San Diego, La Jolla, CA, ²University of California San Diego Department of Pediatrics, La Jolla, CA, ³Family and Preventive Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the…
Abstract Number: 803 • 2013 ACR/ARHP Annual Meeting
The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis
Lucía Silva-Fernández^1,2, Mark Lunt³, Audrey S. Low², Kath D. Watson³, BSRBR Control Centre Consortium², Deborah P. Symmons², Kimme L. Hyrich⁴ and On behalf of the BSRBR⁵, ¹Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁵British Society for Rheumatology, London, United Kingdom
Background/Purpose: In the United Kingdom (UK), rituximab (RTX), an anti-CD20 monoclonal antibody, is currently used to treat patients with rheumatoid arthritis (RA) who have failed…
Abstract Number: 482 • 2012 ACR/ARHP Annual Meeting
B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases
Ilias Lazarou¹, Axel Finckh², Lara Fischer³, Camillo Ribi³, Joerg Seebach³ and Pierre A. Guerne², ¹University Hospitals of Geneva, Geneva, Switzerland, ²Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ³Immunology, University Hospitals of Geneva, Geneva, Switzerland
Background/Purpose: B-Lymphocyte (B-Ly) depletion therapy with the monoclonal anti-CD20 antibody rituximab (RTX) is widely used in a variety of autoimmune (AI) diseases. The risk of…
Abstract Number: 445 • 2012 ACR/ARHP Annual Meeting
Combination of Intra-Articular Steroid Injection and Infliximab More Effective Than Infliximab in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, x Ray Reader Blinded Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kazuhiko Hatta², Kuniki Amano³, Hiroyuki Ohta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Hatta Clinic, Kure, Japan, ³Rheumatology, Sky Clinic, Hiroshima, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, recent publications described rapid radiographic progression (RRP) existed despite initial biologics and methotrexate…
Abstract Number: 177 • 2012 ACR/ARHP Annual Meeting
Antibodies to Citrullinated Peptides in Tuberculosis
Isabella Lima¹, Rodrigo Oliveira², Ajax Atta², Samyra Marchi³, Lúcio Barbosa³, Eliana Reis³, Mitermayer G. Reis³ and Mittermayer Santiago⁴, ¹Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, ²Universidade Federal da Bahia, Salvador, Brazil, ³Fundação Oswaldo Cruz, Salvador, Brazil, ⁴Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetric polyarthritis, rheumatoid factor positivity (RF) in the majority of patients, and bone erosions shown…
Abstract Number: 178 • 2012 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin in Parvovirus B19 Mediated Pure Red Cell Aplasia: A Retrospective Study in 10 Patients and a Review of 123 Cases
Yoann Crabol, Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
Background/Purpose: The efficacy of intravenous immunoglobulin (IVIg) therapy in patients with pure red cell aplasia (PRCA) related to human parvovirus B19 (HPV-B19) infection is mainly…
Abstract Number: 2543 • 2012 ACR/ARHP Annual Meeting
Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents
Jeffrey R. Curtis¹, Shuo Yang², Nivedita M. Patkar³, Lang Chen⁴, Jasvinder A. Singh⁵, Grant W. Cannon⁶, Ted R. Mikuls⁷, Elizabeth S. Delzell⁸, Kenneth G. Saag⁹, Monika M. Safford¹⁰, Scott DuVall¹¹, Kimberly Alexander¹², Pavel Napalkov¹², Aaron Kamauu¹³ and John Baddley¹⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Immunology/Rheumatology, Univ of Alabama-Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁶Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ¹⁰Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹¹VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ¹²Epidemiology, Genentech, Inc., South San Francisco, CA, ¹³Anolinx, Bountiful, UT, ¹⁴Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Risks of hospitalized infections for newer biologic agents have not been well characterized compared to risks for anti-TNF therapy. Purpose: To compare the risk…
Abstract Number: 98 • 2012 ACR/ARHP Annual Meeting
How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report From a Large-Scale Prospective Cohort Study
Hayato Yamazaki¹, Ryoko Sakai¹, Ryuji Koike², Yasunari Miyazaki³, Michi Tanaka¹, Toshihiro Nanki¹, Kaori Watanabe¹, Shinsuke Yasuda⁴, Takashi Kurita⁵, Yuko Kaneko⁶, Yoshiya Tanaka⁷, Yasuhiko Nishioka⁸, Yoshinari Takasaki⁹, Kenji Nagasaka¹⁰, Koichi Amano¹¹, Shigeto Tohma¹², Makoto Dohi¹³, Takahiko Sugihara¹⁴, Haruhito Sugiyama¹⁵, Yasushi Kawaguchi¹⁶, Naohiko Inase¹⁷, Sae Ochi¹⁸, Hiroyuki Hagiyama¹⁹, Nobuyuki Miyasaka²⁰ and Masayoshi Harigai²¹, ¹Department of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁵Department of Medicine II, Hokkaido University, Sapporo, Japan, ⁶Dept of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Department of Respiratory Medicine & Rheumotology, The Univeristy of Tokushima Graduate School, Tokushima, Japan, ⁹Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁰Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ¹¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ¹²Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan, ¹³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ¹⁴Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ¹⁵Division of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan, ¹⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷Dept of Integrated Pulmonology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁸Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, ¹⁹Department of Rheumatology, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, ²⁰Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ²¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Patients with rheumatic diseases given immunosuppressive therapy are susceptible to various types of infections, especially pulmonary infections that affect their vital prognosis. The aim…
Abstract Number: 2452 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated PTPN22 Modulates Toll-Like Receptor-Mediated, Type 1 Interferon-Dependent Innate Immunoregulation
Yaya Wang¹, Stephanie Stanford², Wenbo Zhou³, Jennifer L. Auger⁴, Genhong Cheng⁵, Amanda Campbell⁶, Fernanda M. Shoyama¹, Henry H. Balfour Jr.⁷, Andrew C. Chan⁸, Bryce A. Binstadt⁴, Nunzio Bottini⁶ and Erik J. Peterson³, ¹Department of Medicine, University of Minnesota, Minneapolis, MN, ²Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³University of Minnesota, Minneapolis, MN, ⁴Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, ⁵University of California, Los Angeles, Los Angeles, CA, ⁶La Jolla Institute for Allergy and Immunology, La Jolla, CA, ⁷University of Minnesota, Minneapolis, ⁸Immunology, Genentech Inc, South San Francisco, CA
Background/Purpose: A coding polymorphism (C1858T) in PTPN22 is strongly associated with risk of Rheumatoid Arthritis (RA) and other autoimmune diseases. PTPN22 encodes Lymphoid Phosphatase (Lyp);…
Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting
Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients
Pierre Charles¹, Antoine Néel², Nathalie Tieulié³, Arnaud Hot⁴, Grégory Pugnet⁵, Olivier Decaux⁶, Isabelle Marie⁷, Mehdi Khellaf⁸, Jean-Emmanuel Kahn⁹, Alexandre Karras¹⁰, Jean-Marc Ziza¹¹, Christophe Deligny¹², Colas Tchérakian¹³ and Loic Guillevin¹⁴, ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ²Internal Medicine, Nantes University Hospital, Nantes, France, ³CHU Nice, Nice, France, ⁴Internal Medicine, Edouard Herriot University Hospital, Lyon, France, ⁵Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ⁶Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁷Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, ⁸Internal Medicine, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ⁹Internal Medicine, Foch Hospital, Suresnes, France, ¹⁰Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ¹¹Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹²Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ¹³Service de pneumologie, hôpital Foch, Suresnes, France, ¹⁴Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France
Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…
Abstract Number: 1999 • 2012 ACR/ARHP Annual Meeting
Immunogenicity and Safety of Two Doses of Influenza A H1N1⁄2009 Vaccine in Young Autoimmune Rheumatic Diseases Patients Under 9 Years Old
Guilherme Trudes¹, Nadia E. Aikawa², Lucia M. Campos³, Rosa M.R. Pereira⁴, Julio C. B. Moraes⁵, Ana Cristina Ribeiro⁶, Joao Miraglia⁷, Maria do Carmo S. Timenetsky⁸, Eloisa Bonfa⁴ and Clovis Artur Silva⁹, ¹Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology, University of São Paulo, Sao Paulo, Brazil, ³Pediatric Rheumatology, University of São Paulo Medical School, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁵Rheumatology Divison, University of Sao Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁷Instituto Butantan, Fundação Butantan, São Paulo, Brazil, ⁸Instituto Adolfo Lutz - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In 2010 the Advisory Committee on Immunization Practices from the CDC recommended that all children should receive the trivalent seasonal influenza vaccine containing the…
Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Sima Ahadieh¹, Tina Checchio¹, Thomas Tensfeldt¹, Jonathan French², Sriram Krishnaswami¹, Richard Riese³, Sujatha Menon¹, Mary G. Boy¹ and Jamie L. Geier⁴, ¹Pfizer Inc., Groton, CT, ²Metrum Research Institute, Tariffville, CT, ³Pfizer Inc, Groton, CT, ⁴Epidemiology, Pfizer Inc., New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…
Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Catrina B. Scherrer¹, Anne AF Mannion², Diego Kyburz³, Markus Vogt⁴ and Ines A. Kramers-de Quervain¹, ¹Rheumatology, Schulthess Clinic, Zürich, Switzerland, ²Research Department, Schulthess Clinic, Zürich, Switzerland, ³Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁴Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…
Abstract Number: 1419 • 2012 ACR/ARHP Annual Meeting
Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up
Renata Baronaite Hansen¹ and Søren Jacobsen², ¹Department of Rheumatology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, ²Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of developing coronary heart disease as well as infections. Acute infections have been recognized…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].